Key insights from EBMT 2025, including trends in CAR-T, JACIE developments, and the growing demand for contingency services in cell therapy. Read Biovault’s perspective on what’s shaping the future of the field.
We explore why robust contingency planning is not just a best practice, but an essential component of responsible biomedical research and advanced cellular therapies.
The MHRA has granted Biovault Technical a WDA license, enabling the distribution of medicinal products and advancing cell therapy access in Plymouth and the UK.
Following the publication of a report on the devastating cryogenic freezer failure at the Karolinska Institutet (KI) in Sweden in December 2023, we scrutinise our systems and offer some support.
